Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs

BACKGROUND: The patterns and determinants of saxagliptin use among patients with type 2 diabetes mellitus (T2DM) are unknown in real-world settings. We compared the characteristics of T2DM patients who were new initiators of saxagliptin to those who were new initiators of non-dipeptidyl peptidase-4...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Pharmacol Toxicol
Autors principals: Saine, M Elle, Carbonari, Dena M, Newcomb, Craig W, Nezamzadeh, Melissa S, Haynes, Kevin, Roy, Jason A, Cardillo, Serena, Hennessy, Sean, Holick, Crystal N, Esposito, Daina B, Gallagher, Arlene M, Bhullar, Harshvinder, Strom, Brian L, Re, Vincent Lo
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4404079/
https://ncbi.nlm.nih.gov/pubmed/25889498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40360-015-0007-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars